These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 37744424)
1. SPAG5 Expression Predicts Poor Prognosis and is Associated With Adverse Immune Infiltration in Lung Adenocarcinomas. Xiao G; Xu X; Chen Z; Zeng J; Xie J Clin Med Insights Oncol; 2023; 17():11795549231199915. PubMed ID: 37744424 [TBL] [Abstract][Full Text] [Related]
2. SPAG5 is associated with unfavorable prognosis in patients with lung adenocarcinoma and promotes proliferation, motility and autophagy in A549 cells. Huang R; Li A Exp Ther Med; 2020 Nov; 20(5):77. PubMed ID: 32968434 [TBL] [Abstract][Full Text] [Related]
3. Expression, immune infiltration and clinical significance of SPAG5 in hepatocellular carcinoma: A gene expression-based study. Chen W; Chen X; Li S; Ren B J Gene Med; 2020 Apr; 22(4):e3155. PubMed ID: 31860771 [TBL] [Abstract][Full Text] [Related]
4. Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma. Wang N; Zhu L; Xu X; Yu C; Huang X Comput Struct Biotechnol J; 2022; 20():4390-4401. PubMed ID: 36051873 [TBL] [Abstract][Full Text] [Related]
5. Wang Y; Wen H; Sun D Ann Transl Med; 2022 May; 10(9):519. PubMed ID: 35928739 [TBL] [Abstract][Full Text] [Related]
6. Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma. Chen R; Wang Z; Lu T; Liu Y; Ji Y; Yu Y; Tou F; Guo S Thorac Cancer; 2023 Apr; 14(10):893-912. PubMed ID: 36825773 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates. Wei Q; Miao T; Zhang P; Jiang B; Yan H Front Genet; 2022; 13():984575. PubMed ID: 36159963 [No Abstract] [Full Text] [Related]
8. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. He Z; Feng W; Wang Y; Shi L; Gong Y; Shi Y; Shen S; Huang H Transl Lung Cancer Res; 2023 Mar; 12(3):510-529. PubMed ID: 37057124 [TBL] [Abstract][Full Text] [Related]
9. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle. Tang X; Zhou H; Liu Y Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920 [TBL] [Abstract][Full Text] [Related]
10. High expression of glycolysis-related Yu H; Yu Z; Qin C; Bian T; Shi M J Thorac Dis; 2022 Sep; 14(9):3488-3499. PubMed ID: 36245582 [TBL] [Abstract][Full Text] [Related]
11. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments. Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746 [TBL] [Abstract][Full Text] [Related]
12. Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma. Hou Y; Xiang B; Yang Z; Liu J; Xu D; Geng L; Zhan M; Xu Y; Zhang B Int J Immunopathol Pharmacol; 2023; 37():3946320231202748. PubMed ID: 37731383 [No Abstract] [Full Text] [Related]
13. DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target. Chen M; Zhang S; Wang F; He J; Jiang W; Zhang L J Transl Med; 2024 Feb; 22(1):209. PubMed ID: 38414025 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of Wei D; Sun D; Sirera R; Afzal MZ; Leong TL; Li X; Wang Y Transl Lung Cancer Res; 2023 Jul; 12(7):1517-1538. PubMed ID: 37577299 [TBL] [Abstract][Full Text] [Related]
15. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma. Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642 [TBL] [Abstract][Full Text] [Related]
16. High Expression of Chen Y; Zhou M; Gu X; Wang L; Wang C Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850 [TBL] [Abstract][Full Text] [Related]
17. IL-1 receptor-associated kinase 3 (IRAK3) in lung adenocarcinoma predicts prognosis and immunotherapy resistance: involvement of multiple inflammation-related pathways. Zhou Y; Rao W; Li Z; Guo W; Shao F; Zhang Z; Zhang H; Liu T; Li Z; Tan F; Xue Q; Gao S; He J Transl Lung Cancer Res; 2024 Sep; 13(9):2139-2161. PubMed ID: 39430338 [TBL] [Abstract][Full Text] [Related]
18. The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating Tang XY; Xiong YL; Shi AP; Sun Y; Han Q; Lv Y; Shi XG; Frattini M; Malhotra J; Zheng KF; Liu YJ; Jiang T; Ma N; Zhao JB Transl Lung Cancer Res; 2022 Mar; 11(3):404-419. PubMed ID: 35399566 [TBL] [Abstract][Full Text] [Related]
19. Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma. Guo W; Huai Q; Zhang G; Guo L; Song P; Xue X; Tan F; Xue Q; Gao S; He J Front Oncol; 2020; 10():598437. PubMed ID: 33569346 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of SH2D5 expression in lung adenocarcinoma and its relation to immune cell infiltration. Zhou H; Li S; Lin Y PeerJ; 2023; 11():e15238. PubMed ID: 37187527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]